View of Pathway enrichment and FDA-approved drug repurposing analysis for the treatment of CTNNB1 Syndrome modeled in an SH-SY5Y cell line

Return to Article Details Pathway enrichment and FDA-approved drug repurposing analysis for the treatment of CTNNB1 Syndrome modeled in an SH-SY5Y cell line Download Download PDF